Monitoring Tysabri Therapy: What Tests and Follow-Up Are Needed?
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Science to Specific Drug Safety
If you or a loved one is on Tysabri, you may wonder what tests are needed to watch for PML. Decades of pharmacovigilance have established that regular monitoring with MRI scans and JC virus antibody testing is critical for early detection. This page explains the standard follow-up protocols and what the results mean for your care.
Understanding Tysabri and Its Mechanism of Action
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance that have established a causal link between Tysabri exposure and PML development. The mechanism by which Tysabri increases PML risk involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in conditions like multiple sclerosis but also impairs normal immune surveillance of the brain. The JC virus, which is latent in most individuals, can reactivate and cause PML when immune cells are unable to access the brain to control viral replication. This mechanistic pathway explains why Tysabri-treated patients are at increased risk for PML compared to the general population.
Clinical Evidence Linking Tysabri to PML
Clinical trial evidence demonstrates the occurrence of PML in Tysabri-treated patients. In clinical trials, PML occurred in three patients who received TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 patients with multiple sclerosis who were treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML. These cases establish a temporal relationship between Tysabri exposure and PML development, with onset ranging from weeks to years after starting treatment. Risk factors for PML in Tysabri-treated patients have been identified and are detailed in the prescribing information. Three factors known to increase PML risk include the presence of anti-JCV antibodies, longer treatment duration especially beyond two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies indicates prior exposure to the virus, and patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Risk Mitigation and Regulatory Warnings
The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and a restricted distribution program. The prescribing information includes a boxed warning that TYSABRI increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, TYSABRI is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program ensures that patients are informed of the risks and that monitoring protocols are followed. For affected patients, causation-related considerations involve the timeline between Tysabri exposure and documented harm. PML typically occurs after several months to years of Tysabri treatment, with risk increasing with longer duration. The clinical presentation of PML includes progressive neurological deficits such as weakness, visual changes, cognitive impairment, and seizures. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The prognosis is poor, with PML usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Conclusion: Causation Established
In summary, the evidence establishes that Tysabri causes PML through a well-understood mechanism involving impaired immune surveillance of the brain. The drug's labeling provides clear warnings about this risk, identifies specific risk factors, and mandates monitoring and immediate discontinuation if PML is suspected. Patients and healthcare providers must weigh the expected benefits of Tysabri against the risk of PML when considering treatment.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Tysabri and PML?
Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The drug impairs immune surveillance in the brain, allowing the virus to reactivate. This causal link is established through clinical trials and postmarketing surveillance, as detailed in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the risk factors for developing PML while on Tysabri?
Three key risk factors increase PML risk: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
How is PML diagnosed in Tysabri-treated patients?
PML diagnosis involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Symptoms include progressive neurological deficits such as weakness, visual changes, cognitive impairment, and seizures. Immediate discontinuation of Tysabri is recommended if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.